MDxHealth SA (MDXH) Stock Analysis

Verdict: AVOID

Severe cash burn, $105.8M debt, and suspended 2026 guidance drive extreme delisting and dilution risks, overriding core growth.

Investment score: 16/100

Analysis as of

Is MDxHealth SA stock worth reviewing? The TradeMates thesis

The model would avoid MDXH due to severe balance sheet deficit, sub-1-year cash runway, and suspended guidance triggering delisting and dilution threats.

7-factor investment score

MDxHealth SA opportunities and risks

What speaks for MDXH

What speaks against MDXH

Frequently asked questions about MDxHealth SA (MDXH)

Is MDXH stock a good investment?

The TradeMates model rates MDxHealth SA as AVOID with an investment score of 16/100. The model would avoid MDXH due to severe balance sheet deficit, sub-1-year cash runway, and suspended guidance triggering delisting and dilution threats. This is algorithmic model output, not personal investment advice.

Is MDXH stock a buy?

The TradeMates model verdict for MDXH is AVOID with an investment score of 16/100. Treat this as a model signal to review, not a personal buy recommendation.